The economic burden associated with dry AMD is a powerful, though often overlooked, driver of market innovation and growth in the Dry Age Related Macular Degeneration Amd Market. As a progressive, debilitating disease that primarily affects a high-cost demographic, the total societal expense—encompassing direct medical costs (doctor visits, supplements, procedures) and indirect costs (lost productivity, caregiver burden, and costs associated with disability and vision aids)—is staggering, running into the billions of dollars globally. This immense financial pressure creates a strong economic incentive for governments and health systems to invest in therapies that can delay or halt disease progression. Even a slight reduction in the rate of progression to late-stage geographic atrophy can lead to significant long-term savings in institutional and personal care.

Furthermore, the significant decline in a patient’s quality of life (QOL) due to central vision loss necessitates investment in supportive services, which is a further drain on resources. The introduction of disease-modifying therapies, even at a high initial cost, is fundamentally justified by the potential to preserve functional vision, maintain patient independence, and ultimately reduce the lifelong financial and social costs associated with advanced visual impairment. This economic imperative ensures sustained pharmaceutical interest and governmental support for the dry AMD market.